Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study
Results demonstrate continued increased awareness and intent to prescribe GIMOTI SOLANA BEACH, Calif. and CHICAGO , June 15, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a
View HTML
Toggle Summary Evoke Pharma Announces FDA Orange Book Listing of U.S. Patent for Gimoti®
SOLANA BEACH, Calif. , June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its US patent No. 11,020,361 for Gimoti ® (metoclopramide) nasal spray is now listed in the
View HTML
Toggle Summary Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®
New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
View HTML
Toggle Summary Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray
Evoke is committed to meeting patients online, where they search for answers New campaign leverages Facebook to satisfy significant unmet need for education and community SOLANA BEACH, Calif. and CHICAGO , May 27, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma Appoints Vickie Reed to Board of Directors
SOLANA BEACH, Calif. , May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the appointment of Vickie Reed to the Company’s board of directors.
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2021 Financial Results
Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increase in new prescribers for Gimoti ® New notice of allowance from USPTO to expand Gimoti patent estate SOLANA BEACH, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021
SOLANA BEACH, Calif. , May 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its first quarter 2021 financial results on
View HTML
Toggle Summary Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®
New patent expands intellectual property protection for nasal delivery of metoclopramide SOLANA BEACH, Calif. , April 06, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the
View HTML
Toggle Summary Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis
SOLANA BEACH, Calif. , March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Company will
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results
Encouraging early traction from GIMOTI™ commercial launch SOLANA BEACH, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the
View HTML